Zimbabwe has turned down a significant US healthcare agreement worth 367 million US dollars (£272m) over five years due to Washington's demand for sensitive information.
This rejection came to light after a official document dated December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "unbalanced".
A government representative later clarified that the United States was requesting health data for scientific study and commercial gain but was unwilling to share the resulting advantages from any future vaccines.
"We will now turn to the difficult and regrettable task of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for continued dialogue to secure a deal suitable to both sides so the nation's vital HIV programme can proceed.
Wider Implications
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a high court halted a similar health funding agreement following legal challenges were raised about the security of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump claimed its spending was "wasteful" and his administration was seeking direct bilateral agreements to boost openness and accountability.
Based on statements, Sixteen African countries have to date agreed to these new health pacts, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment via US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"Our nation was requested to provide its genetic material and health information for a long time, with no equivalent assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"Put simply, our country would provide the basic resources for medical research with no certainty that the final treatments would be accessible to our people should a future health crisis arise."
National Interest and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of one-on-one health agreements were disrupting structures previously set up via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage potential pandemics.
"This system is intended to ensure that when a nation provides its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
These objections over the US deal "are not meant as opposition to America," he added.
"We encourage ongoing dialogue with our US partners on how future collaboration might be structured in a way that respects the independence and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but recommended that negotiations should continue considering a large portion of the nation's HIV programmes depended on external financing.
"Where technical issues exist, including those involving data governance or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," it said.
The situation emphasises the ongoing debate between accepting much-needed foreign assistance and protecting national sovereignty in an increasingly data-driven world.